Drug profile · INN
pimavanserin
PIMAVANSERIN
pimavanserin (PIMAVANSERIN) is a serotonin 2a (5-ht2a) receptor inverse agonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — pimavanserin
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
pimavanserin (PIMAVANSERIN) is a serotonin 2a (5-ht2a) receptor inverse agonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 2a (5-HT2a) receptor inverse agonist
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| NMPA | clinical trials | — |
Frequently asked questions
What is pimavanserin?
pimavanserin (PIMAVANSERIN) is a serotonin 2a (5-ht2a) receptor inverse agonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for pimavanserin?
PIMAVANSERIN is a marketed brand name for pimavanserin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pimavanserin?
pimavanserin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.